Volume 10, Issue 2 (7-2012)                   IJRM 2012, 10(2): 155-160 | Back to browse issues page

XML Persian Abstract Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Eryilmaz O G, Sarikaya E, Doganay M, Mollamahmutoglu L, Cicek N. Prolonged GnRH suppression period in controlled ovarian hyperstimulation cycles: Impacts on IVF outcomes?. IJRM 2012; 10 (2) :155-160
URL: http://ijrm.ir/article-1-262-en.html
Prolonged GnRH suppression period in controlled ovarian hyperstimulation cycles: Impacts on IVF outcomes?
Ozlem Gun Eryilmaz * 1, Esma Sarikaya2 , Melike Doganay2 , Leyla Mollamahmutoglu2 , Nedim Cicek2
1- Department of Obstetrics and Gynecology, Zekai Tahir Burak Women Education and Research Hospital, Mithatpasa cad. Hamamonu, Ankara, Turkey , drozlemgun@yahoo.com
2- Department of Obstetrics and Gynecology, Zekai Tahir Burak Women Education and Research Hospital, Mithatpasa cad. Hamamonu, Ankara, Turkey
Abstract:   (2830 Views)
Background: Prolonged GnRH-a administration in IVF cycles may have some advantages related to the treatment outcomes.
Objective: In this study, we aimed to analyse the effect of prolonged gonadotropin releasing hormone agonist (GnRH-a) administration on controlled ovarian hyperstimulation outcomes of in vitro fertilization (IVF) patients.
Materials and Methods: In this retrospective study, 55 patients with a GnRH-a administration period more than 10 days were compared with 55 patients whose same period was ?10 days with respect to the demographic characteristics, metaphase II (MII) oocyte ratio, grade I (GI) embryo ratio, blastocyst ratio, fertilization, implantation, and the clinical pregnancy rates.
Results: The mean hospital visit count of the prolonged GnRH-a patients was 2.6±0.4. As we expected, total GnRH-a doses used during hypophyseal down regulation were significantly different between the groups (p<0.0001). MII oocyte, G1 embryo and the blastocyst ratios were also significantly different between the groups (p<0.0001; p<0.01 and p<0.05). All the other parameters were insignificant.
Conclusion: Prolonged GnRH-a administration during ovarian suppression in IVF patients may have positive impacts on the oocytes and the embryos, but this affect may not be observed in the overall pregnancy rates.
Keywords: GnRH agonist, IVF outcome, Embryo quality
Full-Text [PDF 259 kb]   (729 Downloads) |   |   Full-Text (HTML)  (360 Views)  
Type of Study: Original Article |
References
1. Muasher SJ, Abdallah RT, Hubayter ZR. Optimal stimulation protocols for in vitro fertilization. Fertil Steril 2006; 86: 267-273. [DOI:10.1016/j.fertnstert.2005.09.067]
2. Serafini P, Stone B, Kerin J, Batzofin J, Quinn P, Mars R. An alternate approach to controlled ovarian hyper-stimulation in 'poor responders': pretreatment with a gonadotropin releasing hormone analog. Fertil Steril 1988; 49: 90-95. [DOI:10.1016/S0015-0282(16)59655-1]
3. Huirne AFJ, Schats R. The use of GnRH agonists. In: Gardner KD, Weissman A, Howles CM, Shoham Z. Textbook of assisted reproductive technologies. 3rd Ed. UK; Informa Healthcare; 2009: 529-538.
4. Janssens RM, Lambalk CB, Vermeiden JP, Schats R, Bernards JM, Rekers-Mombarg LT, et al. Dose finding study of triptorelin acetate for prevention of a premature LH surge in IVF: a prospective, randomised, double-blind, placebo-controlled study. Hum Reprod 2000; 15: 2333-2340. [DOI:10.1093/humrep/15.11.2333]
5. Kondaveeti-Gordon U, Harrison RF, Barry-Kinsella C, Gordon AC, Drudy L, Cottell E. A randomized prospective study of early follicular or midluteal initiation of long protocol gonadotropin-releasing hormone in an in vitro fertilization program. Fertil Steril 1996; 66: 582-586. [DOI:10.1016/S0015-0282(16)58571-9]
6. Loutradis D, Kallianidis K, Sakellaropoulos G, Dokos J, Siskos K. Outcome of ovarian response after suppression with a gonadotropin releasing hormone agonist in different chronological periods prior to gonadotropin stimulation for in vitro fertilization. Gynecol Obstet Invest 1991; 32: 68-71. [DOI:10.1159/000292997]
7. Daya S. Gonadotropin-releasing hormone agonist protocols for pituitary desensitization in in-vitro fertilization and gamete intrafallopian transfer cycles (Cochrane review). In: The Cochrane Library, Issue 1. Oxford; Update Software; 2000.
8. Meresman GF, Bilotas MA, Lombardi E, Tesone M, Sueldo C, Branao RI. Effect of GnRH analogues on apoptosis and release of interleukin-I beta and vascular endothelial growth factor in endometrial cell cultures from patients with endometriosis. Hum Reprod 2003; 18: 1767-1771. [DOI:10.1093/humrep/deg356]
9. Chou CS, Tai CJ, MacCalman CD, Leung PC. Dose dependant effects of gonadotropin releasing hormone on matrix metattoproteinase (MMS) -2 and MMP-9 and tissue spesfic inhibitor of matalloproteinase-I massenger ribonucleic acid levels in human decidual stromal cells in vitro. J Clin Endocrinol Metab 2003; 88: 680-688. [DOI:10.1210/jc.2002-021277]
10. Kawamura K, Fukuda J, Kumagai J, Shimizu Y, Kodama H, Nakamura A, et al. Gonadotropin releasing hormone I analogue acts on an antiptotic factor in Mouse blastocysts. Endocrinology 2005; 146: 4105-4116. [DOI:10.1210/en.2004-1646]
11. Torres Mde M, Donadio N, Donadio NF, Brandao AC, Heck B. Comparison of embryo implantation in Wistar rats that underwent ovarian stimulation using exogenous gonadotropins assiciated with cetrorelix acetate and leuprolide acetate. Fertil Steril 2005; 84: 1235-1240. [DOI:10.1016/j.fertnstert.2005.06.012]
12. Klemmt PAB, Liu F, Carver JG, Jones C, Brosi D, Adamson C. Effect of gonadotropin releasing hormone analogues on human endometrial stromal cells and embryo invasion in vitro. Hum Reprod 2009; 24: 2187-2192. [DOI:10.1093/humrep/dep181]
13. Korula G, Mohan S Kamath. Fertility and age. J Hum Reprod Sci 2010; 3: 121-123. [DOI:10.4103/0974-1208.74152]
Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Designed & Developed by : Yektaweb